, to exploit a Ric-8-based technology to purify recombinant G proteins and to use the G proteins in assays

Find the right service provider for your assay, screening, or discovery needs — without wading through

cell surface proteins that mediate Wnt signaling — one of the most fundamental pathways in vertebrate development in 19 Wnt ligands is currently available in a biologically active, tagged form suitable for binding assays compound became the first pharmacological handle on frizzled SAG1.3, a small molecule agonist originally developed The development of a HEK cell line with all class F receptors knocked out — generated by Benoît Vanhollebeke's

Translate project strategy into clear decision-driving assays Eliminate “nice to have” tests that stall

Chris Tate's thermostabilization strategy, which introduced stabilizing mutations selected by thermal assay co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery and development

Sokhom recalls how binding assays at BMS introduced him to the depth and complexity of receptor pharmacology

Premium Members Include: ✔ Drug hunters at early-stage biotechs ✔ CRO leaders building assays and tools

the Forefront of GPCR Drug Discovery Gain insider methods from the pioneers shaping biased signaling, assay Pharmechanics GPCR signaling & biased agonism expert regularly consulted by top pharma companies for assay Weekly GPCR Insights (papers, jobs, events) Networking with a global scientist community One failed assay Aside from his vast experience in drug development, not to mention his extensive publication record, We have a 90% discount for people who live and work in developing countries and a 15% discount for team

During her postdoctoral work, she developed a computational framework that maps communication pathways Nivedha developed computational approaches to quantify ligand bias by analyzing communication routes The lab had developed software to analyze these communication pathways. It also showed me how important GPCR research is in pharmaceutical development. That moment led to the development of the computational method we later published.

Receptor signaling assays showed efficacy shifts in the spinal cord and tolerance attenuation in the

Cell context, assay choice, and receptor conformational heterogeneity all contribute to outcomes.

. 🚀 Develop New GPCR Skills Join Dr. Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential insights into: 🔹 Drug Development Basics – PK-PD insights, absorption, and drug properties 🔹 Clearance He discusses biased signaling in GPCR research, developing biosensors for G protein activity, networking light-sensitive GPCR, bistable opsin Diapause hormone receptor affects larval growth and embryonic development

. 🗓️ Upcoming 4-Week Course: Development of GPCR Ligands as Therapeutic Drugs starting March 20 – April GPCRs GPCR Events, Meetings, and Webinars March 19, 2025 | Advancing obesity drug discovery: Cell-based assays

If you live and work in a developing country, you may qualify for a 90%. If you live and work in a developing country, you can join the global GPCR community with 90% off Premium Researchers in developing countries receive 90% off Premium Memberships, ensuring access to world-class reduced Premium Membership pricing for scientists and professionals based in countries classified as developing 1️⃣ Confirm Your Eligibility This discount applies to individuals who live and work in developing countries

<< Back to podcast list Strategic Partner(s) Developing new tools to uncover GPCR signaling patterns My particular projects revolve around developing new tools to study GPCR activity in ways that were not This research has led to a first-author Cell article on the development of a new biosensor platform called Overall, the lab works on diverse models and diseases, and has developed a wide array of tools to dissect

He is Chief Scientific Officer and co-founder of InterAx Biotech, where he specializes in the development Gebhard Schertler, he developed methods for kinetic mathematical analysis of GPCR signaling. Before focusing on the development of innovative mathematical modeling and simulation methods for drug Aurelien Rizk, a co-founder and CEO of Interax Biotech, shared about the company's development of a discovery of interdisciplinary teamwork in drug and technology development, noting the challenges of communication

His thesis work led to the development and application of light energy transfer methodology to study His research program is developed to understand the signaling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signaling mechanisms in development, adult tissue homeostasis, His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway biotech companies, ModMab Therapeutics , and AntlerA Therapeutics , which are pursuing the clinical development

The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers Cardarelli is a drug development leader with extensive experience driving drug discovery teams in bringing biology, pharmacology, translational medicine, oncology, immuno-oncology, immunology, and clinical development While at BMS and Medarex, she led programs from target ID to clinical development that included, CXCL10 including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic development

At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery and development

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

Its discovery and characterization have led to the development of GLP-1 receptor agonists, a therapeutic Pierce earned her PhD at Creighton University, where she studied the role of microRNAs in inner ear development identifying compounds that modulate neural signaling pathways and may serve as leads for therapeutic development

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

I have 10 years of experience in the development and management of R&D projects and teams in the field I have developed my expertise in the field of pharmacology and biochemistry of GPCR and the crucial role I developed G.CLIPS biotech's innovative technology as a synthesis of the different knowledge, experiences

The conversation also covers what happens when taste pharmacology intersects with drug development - ABOUT THE GUEST Masha Niv is associate professor and vice dean of research and development at the Hebrew Niv's lab developed a machine learning predictor trained on intensely bitter compounds that can flag bitterness risk from chemical structure alone, early in the development pipeline. Niv's lab is developing a recommendation system - trained on known receptor-ligand pairs and the structural

She developed expertise over the past two decades studying structure/function relationships of GPCRs the fundamental knowledge of GPCR biology and for the identification of drug targets and future drug development Manager, where they managed a technical support team providing scientific data analysis and database development contributed analytic support resulting in authorship of numerous scientific publications and new funding, and developed delivered technical presentations and software demonstrations to prospective customers worldwide, and developed

Monash Institute of Pharmaceutical Sciences (MIPS), a collaborative venture targeting new medicines development and CEO of Phrenix Therapeutics, a biotech spin-out from the Neuromedicines Discovery Centre that is developing particularly in the field of psychiatry, where he has led multiple projects into late stage preclinical development

Raimond Heukers , developed a nanobody platform within the research group and used this platform to develop He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA

One example of our recent work surrounds a structure-based effort to develop ligands that specifically Our goal is to develop safer beta2AR-selective ligands for the treatment of asthma and acute rescue therapy The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and Through structural and computational approaches the Sunahara lab and collaborators developed a thermostable

these benefits are designed to enhance your research experience and keep you informed about the latest developments Free Apply as an Instructor Developing Countries Full Premium access for researchers in developing countries Do you offer discounts for students or developing countries? What happens after I join?